Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. Following a separation from its former parent in May 2024, the company operates as a standalone entity with a pipeline centered on ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist. The company has no commercial product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(43,311) | $(78,710) |
| Diluted Net Loss Per Share | $(2.80) | $(5.77) |
| Operating Expenses | $42,901 | $73,825 |
| Research & Development (R&D) | $36,877 | $63,851 |
| General & Administrative (G&A) | $6,024 | $9,974 |
| Cash and Cash Equivalents (End of Period) | $216,520 | $252,483 |
| Long-Term Debt, Net | $98,653 | $0 |
| Accumulated Deficit | $(149,443) | $(692,444) |
Note: Q1 2024 figures reflect the historical financials of the Former Parent, adjusted for the distribution ratio, as the company was not a standalone entity during that period.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by 45% (from $78.7M to $43.3M) primarily due to reduced operating expenses following the separation of the INBRX-101 business in Q2 2024.
- Operating Expense Decline: Total operating expenses dropped 42% ($30.9M decrease).
- R&D Expenses: Decreased 42% ($27.0M), driven by a $16.7M reduction in contract manufacturing and a $6.5M reduction in clinical trial costs associated with the spun-off INBRX-101 program.
- G&A Expenses: Decreased 40% ($4.0M), attributed to lower stock-based compensation, reduced legal fees, and the conclusion of merger-related expenses.
- Debt Financing: In January 2025, the company entered a new $100.0 million loan agreement (2025 Loan Agreement) with Oxford Finance LLC. This replaced the previous debt structure which was assumed by the Acquirer (Sanofi) during the 2024 separation. Interest expense decreased 67% to $2.7M due to the lower principal balance compared to the prior period's $200M debt.
- Cash Flow: Net cash used in operating activities improved significantly to $35.9M (from $63.1M). Financing activities provided $99.8M in cash, primarily from the new debt issuance, resulting in a net cash increase of $63.9M for the quarter.
Guidance, Outlook, and Risks
- Clinical Pipeline Updates:
- Ozekibart (INBRX-109): Phase 2 data for chondrosarcoma expected in Q3 2025. Interim data for Ewing sarcoma and colorectal cancer cohorts anticipated in H2 2025 and Q3 2025, respectively.
- INBRX-106: Phase 2 data for head and neck squamous cell carcinoma (HNSCC) expected in Q4 2025. Positive results could ungate a Phase 3 trial involving ~350 patients.
- Liquidity Outlook: Management believes existing cash and cash equivalents ($216.5M) are sufficient to fund operations for at least 12 months from the filing date. Future capital needs may be met through equity offerings, debt financings, or strategic collaborations.
- Recent Agreements: Entered a License and Assignment Agreement with Scithera, Inc. on March 31, 2025. Potential future milestone payments up to $41.25M and royalties are contingent on funding events and milestones; no revenue recognized in Q1 2025.
- Risk Factors:
- Regulatory & Clinical Risk: Uncertainty regarding clinical trial outcomes, regulatory approvals, and the ability to commercialize products.
- Geopolitical & Economic Risk: New tariffs imposed by the U.S. government in April 2025 may increase raw material costs and disrupt supply chains for clinical drug products.
- Debt Covenants: The 2025 Loan Agreement includes customary covenants and a 9% final payment fee; failure to meet covenants could trigger prepayment.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity projection against current burn rates and potential delays in clinical data readouts.
- Debt Terms: Review the specific covenants and prepayment penalties in the 2025 Loan Agreement with Oxford Finance LLC.
- Clinical Milestones: Monitor the timing and results of the Phase 2 chondrosarcoma trial (ozekibart) and the HNSCC trial (INBRX-106) scheduled for late 2025.
- Scithera Agreement: Track the achievement of funding events required to trigger the $1.3M non-refundable payment and subsequent milestones.
- Tariff Impact: Assess the potential impact of April 2025 U.S. tariffs on the cost of manufacturing clinical supplies and drug product imports.